journal article·2010-07Open access

Investigation of the binding of Cr(III) complexes to bovine and human serum proteins: A proteomic approach

Cathy Tkaczyk, Olga L. Huk, Fackson Mwale, John Antoniou, David J. Zukor, Alain Petit, Maryam Tabrizian

Abstract

Abstract Chromium (Cr) compounds are widely used in alloys manufacturing and forming processes. One of the main concerns in the use of cobalt‐chromium (Co‐Cr) alloy‐based implants is the long‐term fate of Co and Cr ions in the blood, organs, and urine of patients. Our previous studies have shown that Cr(III) forms complexes in different cell culture media, whereas Cr(VI) does not form any detectable structure under the same conditions. Because Cr(VI) is known to be more toxic than Cr(III), we hypothesized that the presence of serum proteins in the molecular structure of Cr(III) may be responsible for the difference in toxicity. We investigated the interaction of the Cr(III) complexes with serum proteins and their internalization by U937 macrophage‐like cells. By using a proteomic approach, we showed that in the presence of fetal bovine serum, Cr(III) complexes interacted only with albumin, whereas they interacted mainly with albumin, transferrin, and immunoglobulins (Ig) in the presence of human serum (HS). Cr(III) complexes were more easily engulfed by U937 macrophage‐like cells when they were formed with HS. To the best of our knowledge, this is the first report on the formation of Cr(III) complexes in the presence of serum proteins and the interaction of these complexes with U937 macrophage‐like cells. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Trace Elements in Health · Chromium effects and bioremediation · Analytical chemistry methods development

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (62)

Show source-provided references
1. 10.1002/ajim.470017020510.1002/ajim.4700170205 ↗
2. 10.1034/j.1600-0536.2002.470608.x10.1034/j.1600-0536.2002.470608.x ↗
3. 10.1016/j.arth.2004.09.00910.1016/j.arth.2004.09.009 ↗
4. 10.2106/00004623-199306000-0000410.2106/00004623-199306000-00004 ↗
5. 10.1302/0301-620X.57B4.44410.1302/0301-620X.57B4.444 ↗
6. 10.1046/j.1365-2133.2003.05404.x10.1046/j.1365-2133.2003.05404.x ↗
7. 10.1002/1097-4636(200009)53:5<480::AID-JBM6>3.0.CO;2-B10.1002/1097-4636(200009)53:5<480::AID-JBM6>3.0.CO;2-B ↗
8. 10.1302/0301-620X.83B8.1275510.1302/0301-620X.83B8.12755 ↗
9. 10.1016/j.tiv.2007.07.01110.1016/j.tiv.2007.07.011 ↗
10. 10.1615/JEnvironPatholToxicolOncol.v20.i2.1010.1615/JEnvironPatholToxicolOncol.v20.i2.10 ↗
11. 10.1002/jbm.a.3088410.1002/jbm.a.30884 ↗
12. 10.1016/j.biomaterials.2006.01.03510.1016/j.biomaterials.2006.01.035 ↗
13. 10.1016/S0959-8049(99)00312-310.1016/S0959-8049(99)00312-3 ↗
14. Local and distant products from modularity
15. 10.1093/toxsci/60.2.19610.1093/toxsci/60.2.196 ↗
16. 10.2106/JBJS.F.0055110.2106/JBJS.F.00551 ↗
17. 10.1021/ac00093a01510.1021/ac00093a015 ↗
18. 10.1007/s10534-008-9165-410.1007/s10534-008-9165-4 ↗
19. 10.1016/S0041-008X(96)80020-210.1016/S0041-008X(96)80020-2 ↗
20. 10.1016/0048-9697(88)90202-110.1016/0048-9697(88)90202-1 ↗
21. 10.1016/j.biomaterials.2008.09.05510.1016/j.biomaterials.2008.09.055 ↗
22. 10.1002/pssa.221072011610.1002/pssa.2210720116 ↗
23. 10.1097/00003086-199608001-0002010.1097/00003086-199608001-00020 ↗
24. 10.1016/j.biomaterials.2004.04.03510.1016/j.biomaterials.2004.04.035 ↗
25. 10.1186/1471-2172-10-1810.1186/1471-2172-10-18 ↗
26. 10.1016/j.immuni.2005.05.00210.1016/j.immuni.2005.05.002 ↗
27. 10.1016/S0142-9612(02)00351-410.1016/S0142-9612(02)00351-4 ↗
28. 10.1016/j.biomaterials.2004.11.01910.1016/j.biomaterials.2004.11.019 ↗
29. 10.1002/cyto.99020010610.1002/cyto.990200106 ↗
30. 10.1021/cr068287r10.1021/cr068287r ↗
31. 10.1016/0009-8981(95)06057-K10.1016/0009-8981(95)06057-K ↗
32. 10.1007/s00775010023810.1007/s007750100238 ↗
33. 10.1007/s00775-005-0647-310.1007/s00775-005-0647-3 ↗
34. 10.1002/chir.2021610.1002/chir.20216 ↗
35. 10.1080/1521654050040409310.1080/15216540500404093 ↗
36. 10.1016/j.jpba.2005.11.03710.1016/j.jpba.2005.11.037 ↗
37. 10.1002/med.1003910.1002/med.10039 ↗
38. 10.1038/186910.1038/1869 ↗
39. The characterization of two specific drug binding sites on human serum albumin10.1016/S0026-895X(25)10691-3 ↗
40. 10.1093/protein/12.6.43910.1093/protein/12.6.439 ↗
41. 10.1080/1071576031000162625710.1080/10715760310001626257 ↗
42. 10.1016/S0162-0134(01)00195-710.1016/S0162-0134(01)00195-7 ↗
43. 10.1073/pnas.043657610010.1073/pnas.0436576100 ↗
44. 10.1385/BTER:96:1-3:12510.1385/BTER:96:1-3:125 ↗
45. 10.1038/nature0642010.1038/nature06420 ↗
46. 10.1016/S0162-0134(98)00010-510.1016/S0162-0134(98)00010-5 ↗
47. 10.1139/o91-12110.1139/o91-121 ↗
48. 10.1111/j.1432-1033.1994.tb18614.x10.1111/j.1432-1033.1994.tb18614.x ↗
49. 10.1021/ja052768v10.1021/ja052768v ↗
50. 10.1016/0301-4622(92)85010-210.1016/0301-4622(92)85010-2 ↗
51. 10.1016/j.ijbiomac.2008.11.00810.1016/j.ijbiomac.2008.11.008 ↗
52. 10.1016/S0065-3233(08)60065-010.1016/S0065-3233(08)60065-0 ↗
53. 10.1016/S1386-1425(00)00313-910.1016/S1386-1425(00)00313-9 ↗
54. 10.1016/S0167-4838(01)00287-410.1016/S0167-4838(01)00287-4 ↗
55. 10.1021/ja07636410.1021/ja076364 ↗
56. N‐lobe versus C‐lobe complexation of bismuth by human transferrin10.1042/bj3370105 ↗
57. 10.1021/bi000798z10.1021/bi000798z ↗
58. Transferrin, the transferrin receptor, and the uptake of iron by cells
59. Influence of sex and age on serum immunoglobulin concentrations in healthy subjects
60. 10.1152/ajpcell.00029.200810.1152/ajpcell.00029.2008 ↗
61. 10.1021/bi00366a00610.1021/bi00366a006 ↗
62. Redistribution of plasma zinc between albumin and alpha 2‐macroglobulin in pregnancy